Why Join Intellia?
Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.
Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.
We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.
We’re looking for a passionate individual to bring their expertise in the sequencing and nucleic acid quantification space. This person will be responsible for the evaluation, onboarding, and execution of molecular technologies and related assays that support our strategic scientific direction. The initial assay focus will be in the broad sequencing (NGS) and nucleic acid quantification space.
The successful candidate will identify, onboard, and execute NGS and other nucleic acid technologies that address the needs underlying the molecular validation of gene therapy and genome editing.
The successful candidate will collaborate with our platform teams to identify and develop appropriate sequencing technologies that will be used to characterize residual impurities in therapeutic candidates
Set up and manage strategic collaborations with CROs or vendors for critical characterization and release assays as needs arise
Work both independently and as part of a collaborative team to design, plan and execute experiments that support development activities, project goals, and platform development
Collaborate with internal research sequencing team to develop analysis methods
Design, execute and troubleshoot experiments
Maintain lab notebooks and reporting data and results to the scientific team
Ph.D. in molecular biology, biochemistry, genetics, gene therapy, immunology or related field with 3+ years of industry experience is required
Demonstrated proficiency with all aspects of NGS technology
Passionate and curious about the use of technology in science with a demonstrated ability to identify and onboard new technology platforms for use in a therapeutic development process ranging from discovery to clinical
Demonstrated understanding of the current therapeutic discovery and development process, especially biologics
Prior experience with quantitative assessment of on-/off-target and cell penetrance for gene editing and/or gene therapy
Experience with, gene editing, automation, and -omics readouts
Prior experience with single-cell technologies beyond sequencing preferred
Experience with delivery of gene editing, gene therapy, or RNA interference technologies in vivo or to ex vivo primary cells is a plus
EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.